While the Boston R&D Hub is relatively young compared to the nearly century-long history of UCB, it represents a continuation and extension of the UCB legacy and our Patient Value Strategy. Read from UCB's Dr. Roger Palframan, Head of External Innovation & U.S. Discovery, on UCB's expanding presence in Boston, Massachusetts and our growing team of talented researchers focused on developing next-generation therapies.

This week, UCB will present at AES2020, the American Epilepsy Society’s (AES) virtual meeting – one of the largest meetings of researchers, scientists, and advocacy groups in the field – where we are proud to showcase the work we have been doing with and on behalf of the epilepsy community. UCB will showcase 15 scientific posters highlighting the latest research on our epilepsy portfolio and pipeline.

• 15 scientific presentations highlight data on BRIVACT^® (brivaracetam) CV, NAYZILAM^® (midazolam) nasal spray CIV, VIMPAT^® (lacosamide) CV, and others, illustrating UCB’s commitment to developing new treatment options for patients in their treatment journey
• UCB’s VIMPAT, recently approved by the U.S. Food and Drug Administration (FDA) as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures (PGTCS), will be highlighted during virtual symposium featuring expert neurology panel